Glucocorticoid Withdrawal Symptoms and Quality of Life in Patients with Systemic Lupus Erythematosus

Table 4

Multivariate linear regression analyses identified the independent factor associated with SLEQoL.

Variables	Adjusted beta (95% CI)	value
Adrenal insufficiency^¶	-5.2 (-33.26-22.93)	0.71
Hypocortisolism^¶	0.99 (0.98-1.01)	0.54
FACIT^§	1.31 (0.76, 1.86)	<0.001
PHO9^§	5.21 (4.32, 6.09)	<0.001
^§	44.38 (33.73, 55.02)	<0.001
PSQI^§	4.23 (3.01, 5.45)	<0.001
^§	16.09 (5.55, 26.62)	<0.003

^¶Adjusting for age, SLE duration, GCS dose, cSLEDAI-2K, SDI, used immunosuppressive agent. ^§Adjusting for , , treatment with GCS/immunosuppressive agent. was analysed with SLEQOL except mood domain. SLE: systemic lupus erythematosus; SLEQoL: systemic lupus erythematosus quality of life; FACIT: functional assessment of chronic illness therapy; PHQ-9: patient health questionnaire; PSQI: Pittsburgh’s sleep quality index; CI: confidence interval; GCS: glucocorticoids; cSLEDAI-2K: SLE Disease Activity Index 2000 (clinical domain); SDI: Systemic Lupus International Collaborating Clinic/American College of Rheumatology Damage Index. indicates moderate-severe depressive symptom; indicates poor sleeper.